Trial · NCT00274781
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | ATO + GO | Responses according to IWG MDS Criteria | 30 | percentage of patients | |
| Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | ATO + GO | Responses according to IWG AML Criteria | 25 | percentage of patients | |
| Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | ATO + GO | Responses according to Both Criteria | 10 | percentage of patients | |
| Overall Survival | ATO (0.25mg/kg) and GO (3mg/m2) | Overall Survival | 9.7 | Full Range .75 to 38 | months |
| Overall Survival | ATO (0.25mg/kg) and GO (3mg/m2) | Responders Overall Survival | 28.6 | Full Range 3.5 to 38 | months |
| Overall Survival | ATO (0.25mg/kg) and GO (3mg/m2) | Nonresponders Overall Survival | 7.6 | Full Range 0.75 to 38 | months |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Patients Who Completed 1 12-Week Cycle (C1) | 17 | participants | |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Patients Who Completed 2 12-Week Cycles (C2) | 7 | participants | |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Discontinue Tx During C1: Patient/Physician Choice | 5 | participants | |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Discontinue Tx During C1: Progressive Disease | 5 | participants | |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Discontinue Tx During C1:Treatment Toxicity | 3 | participants | |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Discontinue Tx After C1: Progressive Disease | 8 | participants | |
| Tolerability | ATO (0.25mg/kg) and GO (3mg/m2) | Discontinue Tx After C1: Treatment Toxicity | 2 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00274781/results